Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,693 shares of the biopharmaceutical company’s stock after buying an additional 2,113 shares during the period. Rakuten Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $20,033,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Provenance Wealth Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 208.0% during the third quarter. Provenance Wealth Advisors LLC now owns 619 shares of the biopharmaceutical company’s stock valued at $469,000 after acquiring an additional 418 shares during the period. Putney Financial Group LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $36,000. Factory Mutual Insurance Co. boosted its stake in shares of Regeneron Pharmaceuticals by 11.1% in the third quarter. Factory Mutual Insurance Co. now owns 28,232 shares of the biopharmaceutical company’s stock worth $21,407,000 after acquiring an additional 2,832 shares during the period. Eads & Heald Wealth Management boosted its stake in shares of Regeneron Pharmaceuticals by 54.8% in the third quarter. Eads & Heald Wealth Management now owns 534 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 189 shares during the period. Finally, Trek Financial LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $221,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on REGN. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Evercore upped their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the stock an “equal weight” rating in a research note on Monday. Piper Sandler increased their price objective on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the company an “overweight” rating in a report on Monday, October 19th. Finally, Weiss Ratings upgraded shares of Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $898.97.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 7,830 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the transaction, the director owned 5,219 shares of the company’s stock, valued at $5,057,680.71. This represents a 60.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $900.00, for a total transaction of $360,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at $542,700. This represents a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 20,789 shares of company stock worth $18,766,698. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Down 4.4%

Shares of REGN opened at $930.67 on Thursday. The stock has a market capitalization of $95.82 billion, a price-to-earnings ratio of 20.55, a price-to-earnings-growth ratio of 1.45 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $991.73. The business’s 50 day simple moving average is $800.69 and its 200-day simple moving average is $741.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% compared to the same quarter last year. During the same period last year, the firm posted $11.83 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 51.64 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.30%.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.